Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Phosphorylcholine Stories

2014-04-10 08:30:25

- First-of-its-Kind Dissolving Medical Device Being Evaluated in People with Blocked Heart Vessels ABBOTT PARK, Ill., April 10, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb(TM) Bioresorbable Vascular Scaffold (BVS) in the United States, Japan and China. Combined, the U.S., Japan and China account for more than 50 percent of the world's heart stent market....

2014-03-05 12:27:46

-- Rapid polymer absorption within three months coupled with drug delivery profile up to nine months provides for excellent healing -- DURHAM, N.C., March 5, 2014 /PRNewswire/ --- Micell Technologies, Inc. today announced that the long-term clinical outcomes from the DESSOLVE I and II clinical trials recently were presented at the Cardiovascular Research Technologies (CRT) Conference held in Washington, D.C., February 22 - 25. The data presentation, "MiStent SES Clinical Program:...

2013-10-28 08:28:49

- Demonstrated Lack of Late Lumen Loss Progression Over 18 Months in Conjunction with Excellent Tissue Healing - DURHAM, N.C., Oct. 28, 2013 /PRNewswire/ -- Micell Technologies, Inc. today announced that imaging and clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(®)) were presented at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference held in San...

2013-05-21 04:20:47

PARIS, May 21, 2013 /PRNewswire/ -- The delayed healing of the coronary artery following physicians' use of drug eluting stents (DES), which increases patients' risks of developing thrombosis, is a top concern today of interventional cardiologists, according to the results of a survey announced at EuroPCR 2013 in Paris. In the online survey of 141 interventional cardiologists in Belgium, China, Denmark, Germany, Italy, Malaysia, The Netherlands, Singapore and the United Kingdom, participants...

2012-11-06 08:27:45

DURHAM, N.C., Nov. 6, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the company's surface and polymer modification technology. This intellectual property protection is related to Micell's investigational MiStent(®) Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(TM)), as well as potential additional biomedical products. The patent rights are assigned to and...

2012-10-23 15:24:23

DURHAM, N.C., Oct. 23, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced positive data from two clinical studies of its investigational MiStent(®) Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(TM)), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed to control drug release. Eighteen-month outcomes from the DESSOLVE I trial, and nine-month data supporting all study endpoints in the DESSOLVE II trial, were...

2012-08-20 02:29:13

ABBOTT PARK, Ill., Aug. 20, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the XIENCE Xpedition(TM) Everolimus Eluting Coronary Stent System received CE Mark in Europe for the treatment of coronary artery disease. The company is launching the product immediately in CE Mark countries. XIENCE Xpedition features a new stent delivery system designed to optimize acute performance, particularly in challenging coronary anatomies. XIENCE Xpedition is supported by the...

2012-07-17 23:00:03

RI Technologies' (http://www.researchimpact.com) exclusive market research update gives an insight into Global Stents and Biodegradable Stents market. The market is divided by Application into Coronary Arterial Stents, Peripheral Arterial Stents and Other; and by Biodegradable Material into Polymer and Metal. Hyderabad, AP (PRWEB) July 17, 2012 Global Biodegradable Stents market is projected to grow at a CAGR of about 70% through the analysis period 2015-2020. With research trials becoming...

2012-05-15 02:29:10

PARIS, May 15, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the XIENCE PRIME(TM) and the XIENCE V® Everolimus Eluting Coronary Stent Systems have received CE Mark in Europe for the use of dual anti-platelet therapy (DAPT) for at least three months after stent implantation in patients with coronary artery disease. This is the shortest duration of DAPT for any major drug eluting stent (DES) in Europe. Patients are prescribed DAPT, a combination of aspirin and...

2012-04-09 02:24:16

ABBOTT PARK, Ill., April 9, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE PRIME, which uses the same drug and biocompatible polymer as the XIENCE V® Everolimus Eluting Coronary Stent System, features an enhanced stent design and a delivery system designed for...